Ethinylestradiol

證據等級: L5

預測適應症: 10 個

Ethinylestradiol: From Oral Contraception to Amenorrhea

One-Sentence Summary

Ethinylestradiol (EE) is a synthetic estrogen that has served as the estrogenic component of combined oral contraceptive pills worldwide for over 60 years, acting on estrogen receptors throughout the body to regulate the hypothalamic-pituitary-ovarian (HPO) axis. The TxGNN model predicts it may be effective for Amenorrhea, with 8 clinical trials and 20 publications currently supporting this direction. Among all 10 predicted indications, amenorrhea carries the strongest clinical evidence (L2) and is the only indication reaching the actionable threshold.

Quick Overview

Item	Content
Original Indication	Oral contraception (estrogenic component of combined oral contraceptives)
Predicted New Indication	Amenorrhea
TxGNN Prediction Score	94.68%
Evidence Level	L2
Singapore Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ethinylestradiol is a synthetic derivative of 17β-estradiol, modified at the C17α position with an ethinyl group to achieve oral bioavailability by resisting first-pass hepatic metabolism. As an estrogen receptor (ERα/ERβ) agonist, EE exerts its principal effects through stimulating endometrial proliferation, modulating pituitary gonadotropin release (FSH/LH) via negative feedback, and — when combined with a progestogen — inducing predictable cyclic withdrawal bleeding.

Amenorrhea (absent or suppressed menstruation) and EE's pharmacological actions are mechanistically tightly coupled. In functional hypothalamic amenorrhea — as seen in athletes with energy deficiency or patients with anorexia nervosa — the HPO axis becomes hypoactive, resulting in insufficient endogenous estrogen. EE directly corrects this deficiency, restoring endometrial responsiveness and enabling cycle-like bleeding when paired with a progestogen. This is precisely the mechanism underlying its use in the estrogen-progestogen challenge test as a diagnostic tool for amenorrhea evaluation.

Beyond deficiency states, clinicians have long used EE-containing preparations therapeutically to induce or suppress menstruation (e.g., in blood dyscrasias where menstrual blood loss poses risk), and in hyperandrogenic conditions such as polycystic ovary syndrome (PCOS) where irregular or absent cycles are common. The mechanistic link is not hypothetical — it is the foundation of how combined oral contraceptives regulate the menstrual cycle. The TxGNN prediction therefore reflects a well-understood pharmacology, not a speculative extrapolation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01103518	Phase 4	Unknown	100	Randomised double-blind comparison of two EE + cyproterone acetate preparations for menstrual irregularities of hyperandrogenic origin — the most directly relevant trial with EE as primary study drug
NCT04831151	N/A	Unknown	42	Compares two EE-containing OC formulations (cyproterone vs drospirenone) on blood metabolomics in PCOS women — directly evaluates EE-based treatment in a population with frequent amenorrhea
NCT00946192	Phase 3	Completed	121	Transdermal vs oral estrogen in adolescent athletes with functional hypothalamic amenorrhea and estrogen deficiency — evaluates estrogen replacement for bone and hormonal outcomes in amenorrheic athletes
NCT00088153	Phase 2/3	Completed	110	Estrogen administration (including EE-containing OC) to adolescent girls with anorexia nervosa-related amenorrhea — assesses hormone replacement for bone density preservation
NCT01588873	Phase 4	Unknown	42	59-week comparison of oral EE-containing OC vs hormonal vaginal ring in PCOS women — evaluates androgen suppression, metabolic effects and cycle regulation
NCT01165307	Phase 4	Completed	77	Medical therapy (OC as a primary option) vs radiofrequency endometrial ablation for menorrhagia — supports EE-based hormonal management of menstrual disorders in a comparative surgical trial
NCT02729545	Phase 2	Completed	60	Acupuncture vs Diane-35 (EE/cyproterone) as active control for PCOS ovarian function — EE arm serves as active comparator, providing safety data in the PCOS/amenorrhea context
NCT00117260	Phase 3	Withdrawn	0	Seasonale (EE-containing extended-cycle OC) for secondary amenorrhea with osteopenia in adolescents — trial was withdrawn before enrolment; no efficacy data available

Literature Evidence

PMID	Year	Type	Journal	Key Findings
5107182	1971	Case Series	Obstet Gynecol	Therapeutic amenorrhea induction using hormonal contraception (including EE-containing preparations) in patients with haematologic disorders to reduce menstrual blood loss — earliest direct clinical use of EE for amenorrhea management
9130733	1997	Clinical Trial	Hum Reprod	GnRH agonist plus EE/CPA vs EE/CPA alone in PCOS hyperandrogenism — demonstrates EE's central role in cycle regulation and androgen suppression in a population with amenorrhoea
15025547	2004	Drug Review	Drugs	Comprehensive profile of EE/chlormadinone acetate — documents efficacy in menstrual regulation, acne, and contraception, including comparison with EE/levonorgestrel
8447356	1993	Review	Am J Obstet Gynecol	Desogestrel/EE tolerability profile — highlights non-contraceptive benefits of EE-containing OC including dysmenorrhoea reduction and menstrual cycle regulation
8324604	1993	Cohort	Br Med Bull	Review of safety and efficacy of combined OC in over 60 million users — documents that health risks are dose-dependent, and discusses menstrual cycle management benefits
3161265	1985	Pharmacodynamic Study	Acta Obstet Gynecol Scand Suppl	Androgenicity of progestogens when combined with EE — specifically addresses PCO-related amenorrhea, obesity and hirsutism as context for EE-progestogen combination selection
65298	1977	Clinical Guidance	Fertil Steril	Systematic diagnostic scheme for primary and secondary amenorrhea — proposes the cyclic estrogen-progestogen (EE-based) test as a key diagnostic step, underpinning EE's mechanistic role
3118717	1987	Review	Am J Obstet Gynecol	Progestogen potency in OC — explains how unopposed EE causes endometrial hyperplasia and amenorrhea; combined cycling produces predictable withdrawal bleeding and acceptable menstrual patterns
12279701	1983	Clinical Review	Lyon Méd	Direct discussion of amenorrhea and the contraceptive pill — addresses post-pill amenorrhea and the use of EE-containing preparations in cycle management
803166	1975	Clinical Review	Fertil Steril	Management of endometriosis in infertile patients — discusses therapeutic amenorrhea induction with EE-based pseudopregnancy and pseudomenopause regimens, extending EE's use beyond contraception

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in this Evidence Pack. Given that EE is a well-established pharmaceutical agent with a long clinical history, clinicians should consult the full prescribing information — particularly regarding thromboembolic risk, cardiovascular contraindications, hormone-sensitive conditions, and interactions with enzyme-inducing medications — before any therapeutic application.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: EE's mechanism of action directly addresses the hormonal deficiency underlying functional hypothalamic amenorrhea, and its use in menstrual cycle regulation is supported by decades of clinical experience, multiple completed Phase 3/4 trials, and an extensive literature base — meeting the L2 evidence threshold (at least one completed Phase 2/3 intervention study). However, EE is not currently registered in Singapore, and comprehensive safety data (TFDA package insert warnings, contraindications, DDI profile) is absent from this pack, preventing full safety gatekeeping.

To proceed, the following is needed:

Obtain full prescribing information (package insert / SmPC) for EE-containing products to complete S1 safety screening — particularly thromboembolic risk, cardiovascular contraindications, and hepatic impairment warnings
Clarify the specific amenorrhea subtype being targeted (functional hypothalamic, hyperandrogenic/PCOS-related, post-pill, or therapeutic), as evidence strength and risk-benefit profiles differ significantly by aetiology
Confirm whether a standalone EE formulation or an EE-containing combination product (with progestogen) is intended, as monotherapy EE carries unopposed oestrogen risk
Assess Singapore regulatory pathway: as EE is not currently marketed, a new marketing authorisation application or compassionate use framework would be required
Conduct mechanistic similarity analysis to the original indication to formalize the rationale for the TxGNN prediction (currently marked as "pending")
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.